# TRUST-III (taletrectinib): what clinicians are saying

> 12 statements from 4 sources (1 video, 2 posts, 1 registry record), 9 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- NCT ID: NCT06564324
- Registry: https://clinicaltrials.gov/study/NCT06564324
- Sponsor: Nuvation Bio Inc.
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: taletrectinib
- Indication: TKI-naïve ROS1-positive locally advanced/metastatic non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 80d8ccd732e265da92d27bf9dd76ff1ef16e2e50fc2df4864d5d457bfb6ebe6e

## Counts

- Commentary sources screened: 10
- Sources cited by verified statements: 4
- Verified statements: 12
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 9
- Findings: 3
- Named people in screened sources (unnamed speakers and accounts not counted): 3
- Speakers cited: 3
- Cited speakers with a verified identity: 3
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 2
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 2
- By role and specialty (the abstract's specialty counts):
  - 1 physician, specialty not confirmed
  - 1 physician, Medical oncology

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist discussing TRUST-III sees taletrectinib as a possible class leader based on earlier-study comparisons, not trial outcomes. A physician who described helping conduct a matching-adjusted indirect comparison interprets it as favoring taletrectinib over crizotinib, but reports comparable severe treatment-related adverse events. The medical oncologist’s praise for CNS activity and neurologic tolerability does not establish an overall safety advantage. The sources reviewed for this edition contain no results from the trial.

## Question clinicians left open

What do clinicians still need to see from TRUST-III on progression-free and overall survival to guide taletrectinib versus crizotinib use in TKI-naïve, locally advanced or metastatic ROS1-positive NSCLC?

From findings F1 (5 statements from 2 speakers in 2 sources) and F3 (4 statements from 1 speaker in 1 source). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Taletrectinib efficacy: what clinicians highlight in indirect TKI-naïve comparisons
  - 5 statements from 2 speakers in 2 sources, 1 of them a podcast or video.
  - 2 of the 2 named speakers in this finding hold this view, each a confirmed clinician.
  - 2 of the report's 2 cited clinicians.
- F2. CNS: what most speakers highlight; a clinician sees similar MAIC grade ≥3 TRAE rates
  - 4 statements from 3 speakers in 3 sources, 1 of them a podcast or video.
  - 2 of the 3 named speakers in this finding hold this view; 1 of the 3 holds its caveat, “a clinician sees similar MAIC grade ≥3 TRAE rates”.
  - 2 of the report's 2 cited clinicians.
- F3. MAIC: a clinician values it pending phase 3 data, but favors direct trials
  - 4 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “favor direct trials”.
  - 1 of the report's 2 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 5 | 4 | 2 | 2 | 3 |
| F2 | 4 | 4 | 3 | 3 | 3 |
| F3 | 4 | 3 | 1 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 2 | 0 | 0 | 2 | 1 | 5 | 2 | 1 post or article, 1 podcast or video |
| F2 | 0 | 0 | 0 | 2 | 2 | 4 | 1 | 2 posts and articles, 1 podcast or video |
| F3 | 3 | 0 | 0 | 0 | 1 | 5 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: PFS (Assessed by BIRC): F1 (3 shared claims), F2 (2 shared claims), F3 (1 shared claims)
- Secondary endpoints: F1 (4 shared claims), F2 (4 shared claims), F3 (1 shared claims)
- Population and setting: F1 (2 shared claims), F2 (2 shared claims), F3 (2 shared claims)
- The comparison: F1 (5 shared claims), F2 (3 shared claims), F3 (1 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (4 shared claims), F3 (1 shared claims)
- Design and conduct: F1 (1 shared claims), F2 (1 shared claims), F3 (3 shared claims)

## Abbreviations

- CNS: central nervous system
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- PFS: progression-free survival
- TKI: tyrosine kinase inhibitor

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 3 | Titles free |
| Detailed analysis | 4 sections | Paid |
| Verified statements with short source quotes and links | 12 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 2 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 3 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 7 | Free |
| Sources with links | 4 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 2 of the 3 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

7 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: PFS (Assessed by BIRC) | discussed | 3 | 2 |
| Secondary endpoints | discussed | 6 | 3 |
| Population and setting | discussed | 3 | 2 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 6 | 3 |
| Safety and tolerability | discussed | 4 | 3 |
| Design and conduct | discussed | 3 | 1 |
| Role of MAIC and real-world analyses alongside direct comparisons | discussed | 4 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 7 statements · 58%** | | | |
| YouTube | 7 | 1 | 1 |
| Podcasts | 0 | 0 | 1 |
| **Posts · 3 statements · 25%** | | | |
| X threads | 3 | 2 | 8 |
| **Primary sources · 2 statements · 17%** (cited for context, not screened) | | | |
| Registry (primary source, cited for context) | 2 | 1 | not screened |

- Screened window: 2024-10-15 to 2026-10-29
- Cited window: 2025-04-07 to 2025-08-27
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kinase Inhibitor (Crizotinib) in TKI-Naïve Patients With ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRUST-III)
- Registry: NCT06564324 (https://clinicaltrials.gov/study/NCT06564324)
- Study IDs: AB-106-G318
- Sponsor: Nuvation Bio Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 194 (estimated)
- Start: 2024-11-27 (actual)
- Primary completion: 2029-01 (estimated)
- Primary endpoint: PFS (Assessed by BIRC) (About 49 months)
- Intervention: Taletrectinib (drug)
- Intervention: Crizotinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 4 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 44 sources about other trials or topics are not included; 1 source that may describe the trial without naming it was not read; discussion that uses a name the trial shares with other things, without the trial's condition or setting, may be missing.
- The summarized views come from three commentary sources and cannot establish the prevalence of an opinion among HCPs.
- No separate protocol or exact-trial results publication was among the sources reviewed. The registry material describes planned methods, not observed TRUST-III outcomes.
- The authors' descriptions of an ongoing comparison and absent direct data are dated to their 2025 posts and interview; they do not establish current trial status.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 12 verified statements · 9 from 2 confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/trust-iii-nct06564324/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=trust-iii-nct06564324

## Cite

Erudio Health. TRUST-III (NCT06564324): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/trust-iii-nct06564324

## Questions

### How much does the TRUST-III report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the TRUST-III report cover?

12 statements from 4 sources (1 video, 2 posts, 1 registry record), 9 of them from 2 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the TRUST-III report?

Its preview, yes: get_report_card({ "slug": "trust-iii-nct06564324" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the TRUST-III report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/trust-iii-nct06564324.json
- Markdown: https://www.erudio.com/reports/trust-iii-nct06564324.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/trust-iii-nct06564324/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "trust-iii-nct06564324"}`
